米力农联合低分子肝素治疗肺心病伴顽固性心力衰竭的疗效观察  

Observation of the efficacy of milinon and low molecular weight heparin in the treatment of pulmonary heart disease combined refractory heart failure

作　　者：杨大鹏 YANG Da-peng(Department of Cardiovascular Surgery,Wuwei People's Hospital,Gansu Province Wuwei 733000,China)

机构地区：[1]武威市人民医院胸心血管外科

出　　处：《临床医药文献电子杂志》2019年第65期13-15,共3页Electronic Journal of Clinical Medical Literature

摘　　要：目的探讨米力农联合低分子肝素对肺心病伴顽固性心力衰竭的疗效,为该病的临床医学治疗提供参考。方法选取108例肾肺心病伴顽固性心力衰竭患者,随机分为对照组和低剂量实验组与高级两实验组三组,每组36人。对照组给予患者常规治疗,包括抗炎、祛痰、强心、利尿等措施,同时给予纠正患者电解质紊乱、酸碱度失衡。低剂量实验组在对照组治疗措施基础上,给予患者静滴注入米力农注射液50μg/kg,推注时间10 min,维持滴注速度0.375μg/(kg·min),1次/d。皮下注射低分子肝素钠50~100 U/kg,1次/d,疗程2周。高剂量实验组在对照组治疗措施基础上,给予患者静滴注入米力农注射液50μg/kg,推注时间10 min,维持滴注速度0.375μg/(kg min),1次/d。皮下注射低分子肝素钠110~150 U/kg,1次/d,疗程2周。结果疗程结束后,实验组总治愈率明显高于对照组,低剂量实验组与高剂量实验组的总治愈率分别为91.67%、94.44%,均优于对照组的总治愈率61.11%,差异有统计学意义(P<0.05)。但两实验组总治愈率比较,差异无统计学意义(P>0.05)。两实验组患者的血液指标与心功能指标改善情况相比较,差异无统计学意义(P>0.05)。低剂量实验组不良反应发生率明显低于与高剂量实验组,分别为5.56%、19.44%,差异有统计学意义(P<0.05)。结论米力农联合低分子肝素对肺心病伴顽固性心力衰竭的疗效显著,明显优于常规治疗,但临床建议采用米力农联合低剂量低分子肝素的方案进行治疗。Objective To observation the efficacy of milinon and low molecular weight heparin in the treatment of pulmonary heart disease combined refractory heart failure.Methods 108 patients with pulmonary heart disease combined refractory heart failure were randomly divided into three groups,control group,low dose group and high dose group,with 36 patients in each group.All the patients received two-week treatment.Patients in control group received the conventional treatment,containing anti-inflammatory,phlegm,heart,diuretic,etc.And these patients also received treatments of correcting electrolyte imbalance and pH imbalance in patients.Besides treatments in control group,patients in low dose group received the treatment of milinon and low molecular weight heparin.The dose of milinon,which used intravenous injection at a speed of 0.375μg/(kg·min),was 50μg/kg,once per day.The dose of low molecular weight heparin,which was administered by subcutaneous injection,was 50-100U/kg,once per day.Patients in high dose group received the same treatment used in low dose group,except for the a higher dose of low molecular weight heparin.It became 110-150U/kg,also once per day.Results The difference of cure rate among the three groups was significant.The difference between control group and low dose group and the difference between control group and high dose group B were statistically significant(P<0.05),while the difference between low dose group and high dose group was not statistically significant(P>0.05).As for the adverse reactions in test groups,the incidence of low dose group was lower than that of high dose group.They were 5.56%and 19.44%,respectively.And the difference between them was statistically significant(P<0.05).Conclusion Efficacy of milinon and low molecular weight heparin in the treatment of pulmonary heart disease combined refractory heart failure is better than that of conventional treatments.Milinon and low dose of low molecular weight heparin is encouraged in case of pulmonary heart disease combined refractory

关 键 词：米力农 低分子肝素 肺心病心力衰竭 

分 类 号：R969.4[医药卫生—药理学]